NCT04745143View on ClinicalTrials.gov

Monotherapy of an NMDA Enhancer for Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Schizophrenia
Interventions
DRUG

NMDAE

Use of an NMDA enhancer for the treatment of schizophrenia

DRUG

Placebo Cap

Use of placebo as a comparator

Trial Locations (1)

Unknown

RECRUITING

Department of Psychiatry, China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

National Health Research Institutes, Taiwan

OTHER

lead

China Medical University Hospital

OTHER